Modulation of seizures and synaptic plasticity by adenosinergic receptors in an experimental model of temporal lobe epilepsy induced by pilocarpine in rats

被引:44
作者
Vianna, EPM
Ferreira, TT
Doná, F
Cavalheiro, EA
Fernandes, MJD
机构
[1] Univ Fed Sao Paulo, Dept Neurol & Neurocirurg, BR-04023900 Sao Paulo, Brazil
[2] Univ Fed Sao Paulo, Disc Neurol Expt, BR-04023900 Sao Paulo, Brazil
[3] Univ Fed Sao Paulo, Dept Biofis, BR-04023900 Sao Paulo, Brazil
关键词
adenosine receptors; ecto-5 '-nucleotidase; status epilepticus; pilocarpine model; temporal lobe epilepsy;
D O I
10.1111/j.1528-1167.2005.01027.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: Adenosine is a major negative neuromodulator of synaptic activity in the central nervous system and can exert anticonvulsant and neuroprotective effects in many experimental models of epilepsy. Extracellular adenosine can be formed by a membrane-anchored enzyme ecto-5'-nucleotidase. The purposes of this study were to characterize the role of adenosine receptors in modulating status epilepticus (SE) induced by pilocarpine and evaluate its neuroprotective action. Ecto-5'-nucleotidase activity was studied during the different phases of pilocarpine-induced epilepsy in rats. Methods: Adult rats were pretreated with different adenosinergic agents to evaluate the latency and incidence of SE induced by pilocarpine in rats. The neuroprotective effect also was evaluated. Results: A proconvulsant effect was observed with DPCPX and DMPX that reduced the latency of SE in almost all rats. Pretreatment with the MRS 1220 did not alter the incidence of SE but reduced the latency to develop SE. An anticonvulsant and neuroprotective effect was detected with R-PIA. Rats pretreated with R-PIA had a decreased number of apoptotic cells in the hippocampus, whereas Pretreatment with DPCPX did not modify the hippocampal damage. An intensification of neuronal death was observed in the dentate gyrus and CA3 when rats were pretreated with DMPX. MRS-1220 did not modify the number of apoptotic cells in the hippocampus. An increase in the ecto-5'-nucleotidase staining was detected in the hippocampus during silent and chronic phases. Conclusions: The present data show that adenosine released during pilocarpine-induced SE via A1-receptor stimulation can exhibit neuroprotective and anticonvulsant roles. Similar effects could also be inferred with A2a and A3 adenosinergic agents, but further experiments are necessary to confirm their roles. Ecto-5'-nucleotidase activity during silent and chronic phases might have a role in blocking spontaneous seizures by production of inhibitory neuromodulator adenosine, besides taking part in the mechanism that controls sprouting.
引用
收藏
页码:166 / 173
页数:8
相关论文
共 65 条
  • [1] Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative disease
    Abbracchio, MP
    Cattabeni, F
    [J]. NEUROPROTECTIVE AGENTS: FOURTH INTERNATIONAL CONFERENCE, 1999, 890 : 79 - 92
  • [2] ESTIMATION OF NUCLEAR POPULATION FROM MICROTOME SECTIONS
    ABERCROMBIE, M
    [J]. ANATOMICAL RECORD, 1946, 94 (02): : 239 - 247
  • [3] Bailly YJ, 1998, SYNAPSE, V29, P279
  • [4] CYTOTOXICITY OF MICROGLIA
    BANATI, RB
    GEHRMANN, J
    SCHUBERT, P
    KREUTZBERG, GW
    [J]. GLIA, 1993, 7 (01) : 111 - 118
  • [5] Neonatal cerebral hypoxia-ischemia: The effect of adenosine receptor antagonists
    Bona, E
    Aden, U
    Gilland, E
    Fredholm, BB
    Hagberg, H
    [J]. NEUROPHARMACOLOGY, 1997, 36 (09) : 1327 - 1338
  • [6] Changes in synaptosomal ectonucleotidase activities in two rat models of temporal lobe epilepsy
    Bonan, CD
    Walz, R
    Pereira, GS
    Worm, PV
    Battastini, AMO
    Cavalheiro, EA
    Izquierdo, I
    Sarkis, JJF
    [J]. EPILEPSY RESEARCH, 2000, 39 (03) : 229 - 238
  • [7] Brundege J M, 1997, Adv Pharmacol, V39, P353, DOI 10.1016/S1054-3589(08)60076-9
  • [8] CAVALHEIRO EA, 1987, POL J PHARMACOL PHAR, V39, P537
  • [9] THE PILOCARPINE MODEL OF EPILEPSY
    CAVALHEIRO, EA
    [J]. ITALIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1995, 16 (1-2): : 33 - 37
  • [10] CERUTI S, 1996, DRUG DEVELOP RES, V3, P177